Results 241 to 250 of about 102,835 (293)

Socio‐demographic and clinical factors associated with the receipt of anti‐obesity medication prescriptions and metabolic and bariatric surgery among eligible all of Us participants

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims There is a paucity of data on socio‐economic characteristics associated with the use of anti‐obesity medications (AOM) and metabolic and bariatric surgery (MBS) when accounting for clinical factors. This study characterized factors associated with the receipt of AOM prescriptions and MBS.
Olajide A. Adekunle   +6 more
wiley   +1 more source

The prevalence of high risk of obstructive sleep apnea in patients with psoriasis. [PDF]

open access: yesSleep Breath
Supajarupan T   +5 more
europepmc   +1 more source

Real‐world insights into incretin‐based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross‐sectional study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This cross‐sectional study examined associations between self‐reported taste perception changes and appetite‐related outcomes in individuals with obesity treated with glucagon‐like peptide‐1 receptor agonist (GLP‐1 RAS) or dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 RAS in real‐world conditions.
Ali Kapan   +4 more
wiley   +1 more source

Supine position-related obstructive sleep apnea in children: insights from the Childhood Adenotonsillectomy Trial. [PDF]

open access: yesSleep Breath
Dai S   +8 more
europepmc   +1 more source

Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Globally, cardiovascular diseases (CVDs) account for around one‐third of all deaths. Clinical trial evidence suggests that treatment of people with obesity or type 2 diabetes (T2D) and CVD with glucagon‐like peptide‐1 (GLP‐1) receptor agonists reduces the risk of major adverse cardiovascular events, heart failure outcomes and all‐cause ...
Naveed Sattar   +5 more
wiley   +1 more source

Weight reduction over time in tirzepatide‐treated participants by early weight loss response: Post hoc analysis in SURMOUNT‐1

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The objective was to assess weight reduction at Weeks 24 and 72 in participants treated with tirzepatide based on weight reduction response after 12 weeks of treatment in the SURMOUNT‐1 trial. Materials and Methods This post hoc analysis included participants treated with tirzepatide who received ≥75% of the assigned treatment doses and ...
Jamy Ard   +9 more
wiley   +1 more source

Obstructive sleep apnea severity and pathophysiological traits in overlap syndrome: Insights from the SNOOzzzE cohort. [PDF]

open access: yesPhysiol Rep
Raphelson J   +12 more
europepmc   +1 more source

Neuronal oscillatory imbalances in GNAO1‐related disorders associated with disease severity

open access: yesEpilepsia, EarlyView.
Abstract Objective This study investigates excitatory/inhibitory (E/I) imbalances in GNAO1‐related disorders (GNAO1‐RD), linking neuronal dysfunction to clinical severity using E/I‐sensitive electroencephalography (EEG) analyses. Methods We conducted an observational study involving 12 children with GNAO1‐RD caused by pathogenic variants and 36 age ...
Tongyu Wang   +8 more
wiley   +1 more source

Hypertension in obstructive sleep apnea: the hidden role of renin-angiotensin-aldosterone system dysregulation. [PDF]

open access: yesTrop Med Health
Loh HH   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy